MX2022016591A - Moléculas de anticuerpo contra april y usos de las mismas. - Google Patents

Moléculas de anticuerpo contra april y usos de las mismas.

Info

Publication number
MX2022016591A
MX2022016591A MX2022016591A MX2022016591A MX2022016591A MX 2022016591 A MX2022016591 A MX 2022016591A MX 2022016591 A MX2022016591 A MX 2022016591A MX 2022016591 A MX2022016591 A MX 2022016591A MX 2022016591 A MX2022016591 A MX 2022016591A
Authority
MX
Mexico
Prior art keywords
antibody molecules
april
treat
disclosed
prevent
Prior art date
Application number
MX2022016591A
Other languages
English (en)
Spanish (es)
Inventor
Zachary Shriver
Gregory Babcock
James R Myette
Boopathy Ramakrishnan
Hedy Adari-Hall
Jill Yarbrough
Asher Schachter
Karthik Viswanathan
Andrew M Wollacott
Mohit Mathur
Original Assignee
Visterra Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Visterra Inc filed Critical Visterra Inc
Publication of MX2022016591A publication Critical patent/MX2022016591A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
MX2022016591A 2020-06-24 2021-06-24 Moléculas de anticuerpo contra april y usos de las mismas. MX2022016591A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063043558P 2020-06-24 2020-06-24
US202063091002P 2020-10-13 2020-10-13
US202163136950P 2021-01-13 2021-01-13
US202163195527P 2021-06-01 2021-06-01
PCT/US2021/038924 WO2021262999A1 (en) 2020-06-24 2021-06-24 Antibody molecules to april and uses thereof

Publications (1)

Publication Number Publication Date
MX2022016591A true MX2022016591A (es) 2023-04-20

Family

ID=77022225

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022016591A MX2022016591A (es) 2020-06-24 2021-06-24 Moléculas de anticuerpo contra april y usos de las mismas.

Country Status (11)

Country Link
US (1) US20260116988A1 (https=)
EP (1) EP4172206A1 (https=)
JP (1) JP2023531722A (https=)
KR (1) KR20230042273A (https=)
AU (1) AU2021297315A1 (https=)
BR (1) BR112022026639A2 (https=)
CA (1) CA3187823A1 (https=)
MX (1) MX2022016591A (https=)
PH (1) PH12023550198A1 (https=)
TW (1) TW202216195A (https=)
WO (1) WO2021262999A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3380522T3 (fi) 2015-11-25 2024-01-16 Visterra Inc Vasta-ainemolekyylejä april-proteiinille ja niiden käyttöjä
US20240092921A1 (en) * 2022-04-25 2024-03-21 Visterra, Inc. Antibody molecules to april and uses thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
DE3689123T2 (de) 1985-11-01 1994-03-03 Xoma Corp Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung.
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP0436597B1 (en) 1988-09-02 1997-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8905669D0 (en) 1989-03-13 1989-04-26 Celltech Ltd Modified antibodies
WO1991000906A1 (en) 1989-07-12 1991-01-24 Genetics Institute, Inc. Chimeric and transgenic animals capable of producing human antibodies
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
DK0585287T3 (da) 1990-07-10 2000-04-17 Cambridge Antibody Tech Fremgangsmåde til fremstilling af specifikke bindingsparelementer
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DE69133557D1 (de) 1990-08-29 2007-03-15 Pharming Intellectual Pty Bv Homologe rekombination in säugetier-zellen
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
EP1820858B1 (en) 1991-03-01 2009-08-12 Dyax Corporation Chimeric protein comprising micro-protein having two or more disulfide bonds and embodiments thereof
ATE414768T1 (de) 1991-04-10 2008-12-15 Scripps Research Inst Bibliotheken heterodimerer rezeptoren mittels phagemiden
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
DK1621554T4 (da) 1992-08-21 2012-12-17 Univ Bruxelles Immunoglobuliner blottet for lette kæder
FI3380522T3 (fi) 2015-11-25 2024-01-16 Visterra Inc Vasta-ainemolekyylejä april-proteiinille ja niiden käyttöjä
HRP20260151T1 (hr) 2016-08-02 2026-03-27 Visterra, Inc. Modificirani polipeptidi i njihova uporaba

Also Published As

Publication number Publication date
JP2023531722A (ja) 2023-07-25
AU2021297315A1 (en) 2023-02-02
BR112022026639A2 (pt) 2023-05-09
CA3187823A1 (en) 2021-12-30
EP4172206A1 (en) 2023-05-03
TW202216195A (zh) 2022-05-01
PH12023550198A1 (en) 2024-06-24
WO2021262999A1 (en) 2021-12-30
KR20230042273A (ko) 2023-03-28
US20260116988A1 (en) 2026-04-30

Similar Documents

Publication Publication Date Title
ZA201803366B (en) Antibody molecules to april and uses thereof
PH12019502875A1 (en) Antibody molecules to cd73 and uses thereof
WO2019232244A3 (en) Antibody molecules to cd73 and uses thereof
ZA202208280B (en) Antibody molecules to c5ar1 and uses thereof
PH12020550141A1 (en) Antibody molecules to cd138 and uses thereof
PH12018501206A1 (en) Antibody molecules to pd-1 and uses thereof
MY187246A (en) Antibody molecules to lag-3 and uses thereof
WO2017181098A3 (en) Antibody molecules to zika virus and uses thereof
WO2017019894A8 (en) Combination therapies comprising antibody molecules to lag-3
MX2020002694A (es) Moleculas de anticuerpo que se unen a tim-3 y usos de las mismas.
WO2020257289A3 (en) Humanized antibody molecules to cd138 and uses thereof
WO2022046922A3 (en) Antibody molecules that bind to nkp30 and uses thereof
MX2020003219A (es) Anticuerpos que tienen especificidad para btn2 y usos de los mismos.
PH12023550198A1 (en) Antibody molecules to april and uses thereof
ZA202106807B (en) Antibodies having specificity for btn2 and uses thereof
PH12021552414A1 (en) Anti fgf23 antibody
MX2019007356A (es) Polipeptidos de union y metodos para fabricarlos.
PH12020552202A1 (en) Antibody molecules to complement component 5 and uses thereof
EA202090891A1 (ru) Молекулы антител против cd138 и их применение
HK1232551A1 (en) Antibody moleules to dengue virus and uses thereof